CA
NZ
UK
AU
IND
US
Single-Patient Case Study Highlights Early Signal for Phyto-N in Cancer CachexiaCuranex Pharmaceuticals drew market attention after presenting a single-patient case study suggesting potential symptomatic benefits of its lead candidate, Phyto-N, in cancer cachexia and advanced cancer supportive care. The patient, treated for a pancreatic …
BioXcel Therapeutics has initiated patient enrollment in a Phase 2a clinical trial evaluating BXCL501 for acute stress reactions (ASR), marking a notable step in the company’s effort to expand its neuroscience pipeline. The study, funded by the U.S. Department of War and led by …
AI Nose Healthcare Deployment Signals Strategic Expansion into High-Value InfrastructureAinos, Inc. (NASDAQ: AIMD) has announced a partnership with MacKay Memorial Hospital and Topco Scientific to deploy its AI Nose technology across critical hospital environments. This move marks a notable extension of its Smell AI …
PMGC Holdings’ full utilization of its $20 million equity purchase facility with Streeterville Capital marks a notable step in reinforcing its balance sheet. The transaction provides incremental liquidity to support near-term acquisitions and integration efforts, while signaling management’s intent to actively deploy capital across …
enGene Therapeutics Name Change Reflects Commercial Transition StrategyenGene’s decision to rebrand from enGene Holdings Inc. to enGene Therapeutics Inc. marks a strategic inflection point as the company moves closer to potential commercialization. The name change, effective April 8, 2026, aligns with its evolving identity …
The broader market context reveals heightened regulatory scrutiny of consolidation within specialized medical device sectors, particularly markets where a small number of competitors dominate. The FTC's determination that the merger would reduce competition and innovation in femtosecond laser-assisted cataract surgery (FLACS) systems demonstrates the …
CytomX is a clinical-stage biopharmaceutical company developing antibody-drug conjugates (ADCs) based on its proprietary PROBODY platform technology, which uses conditional activation to improve drug selectivity and reduce off-target toxicity. The company is transitioning from a collaboration-focused model (with major partners including Bristol Myers Squibb, …
For investors seeking exposure to innovative biopharmaceutical companies with potential breakthrough therapies, EDSA presents a compelling opportunity to invest in a company with near-term regulatory catalysts and multiple shots on goal across its pipeline. The company's focus on inflammatory and immune-related diseases addresses substantial …
This dramatic move underscores the broader market appetite for breakthrough diagnostic tools that can identify life-threatening diseases at earlier, more treatable stages. For investors seeking exposure to the emerging diagnostics sector, BIAF represents a compelling case study of how innovative medical technology can rapidly …
Agenus Inc (NASDAQ:AGEN) stock surged 21.28% to $3.99 on March 17, 2026, driven by investor enthusiasm following the company's announcement of a transformative strategic collaboration with Zydus Lifesciences to advance its flagship botensilimab and balstilimab (BOT+BAL) immunotherapy program. The $141 million partnership, including $75 …
Please wait processing your request...